Welcome to our dedicated page for LianBio news (Ticker: LIAN), a resource for investors and traders seeking the latest updates and insights on LianBio stock.
LianBio (LIAN) is a biotechnology innovator focused on delivering transformative therapies to patients in China and major Asian markets through strategic global partnerships. This news hub provides investors, researchers, and healthcare professionals with timely updates on the company's clinical advancements and operational developments.
Access comprehensive coverage of LianBio's progress across key therapeutic areas including oncology, ophthalmology, and inflammatory diseases. The platform aggregates essential updates including clinical trial milestones, regulatory submissions, partnership announcements, and strategic business decisions. Our curated news selection enables stakeholders to track the company's efforts in addressing critical unmet medical needs through precision therapeutics.
Key areas of focus include developments in LianBio's pipeline candidates, collaborations with international biopharmaceutical leaders, and progress toward bringing innovative treatments to underserved populations. Users will find verified information on drug development timelines, regulatory interactions, and market expansion strategies.
Bookmark this page for streamlined access to official press releases and objective reporting on LianBio's mission to bridge healthcare gaps in Asian markets. For complete details on corporate initiatives, visit the company's official website through the provided link.
LianBio (LIAN) announced the completion of enrollment in the Phase 3 EXPLORER-CN trial for mavacamten, a treatment for hypertrophic cardiomyopathy, with data expected in mid-2023. In China, they initiated pivotal trials for TP-03 and NBTXR3, targeting Demodex blepharitis and head & neck cancer, respectively. LianBio reported a cash balance of $331.8 million as of September 30, 2022, with a runway extending into the second half of 2024. The company aims to launch its first product in 2024, marking significant progress in its clinical pipeline.
LianBio (Nasdaq: LIAN), a biotechnology company focused on innovative medicines for China and Asia, announced participation in several key conferences from November 14-18, 2022. Events include the BioCentury-BayHelix East-West Biopharma Summit, Goldman Sachs Asia Pacific Healthcare Forum, and Jefferies London Healthcare Conference. Notable sessions feature discussions on biotech and capital markets, alongside company presentations and 1:1 meetings. A live audio webcast will be available for the Jefferies conference via LianBio’s investor website.
LianBio (Nasdaq: LIAN) has initiated a Phase 1 clinical trial of BBP-398, a SHP2 inhibitor, in Chinese patients with advanced solid tumors. This two-part study will assess safety, pharmacokinetics, and preliminary anti-tumor activity. Targeting the overactive SHP2 protein, which contributes to cancer resistance, BBP-398 aims to enhance treatment for patients, particularly those with EGFR-mutant non-small cell lung cancer (NSCLC). The company also plans to explore BBP-398 in combination with EGFR inhibitors, with trials expected to begin in 2023.
LianBio (Nasdaq: LIAN) announced the dosing of the first patient in the Phase 3 LIBRA clinical trial for TP-03, targeting Demodex blepharitis in China. With an estimated 43 million patients affected, there are currently no approved treatments in China or the U.S. TP-03 demonstrated significant results in prior U.S. trials, meeting all primary and secondary endpoints. The LIBRA trial aims to enroll 162 patients, with topline results expected in Q4 2023, potentially setting a new standard of care for this condition.
Nanobiotix announced operational progress in its pivotal Phase 3 study, NANORAY-312, focusing on elderly patients with locally advanced head and neck cancer. The first patient has been enrolled in Asia, with plans to recruit approximately 100 patients globally. Financially, the company reported €63 million in cash equivalents as of June 30, 2022, and expects funding through Q1 2024 due to a debt restructuring with the EIB. Despite a stable revenue of €1.3 million, R&D expenses rose to €16.6 million. The net loss decreased to €26.4 million, or €0.76 per share, compared to €30.4 million in 2021.
Nanobiotix and LianBio have announced the enrollment of the first patient in the pivotal Phase 3 NANORAY-312 trial for NBTXR3, targeting elderly patients with locally advanced head and neck cancer ineligible for platinum-based chemotherapy. This trial will assess the effectiveness of NBTXR3 combined with radiotherapy and cetuximab. With a global enrollment goal of 500 patients, LianBio aims to enroll approximately 100 in Asia. Previous trials show promising survival rates, positioning NBTXR3 as a potential key treatment in a rapidly growing radiotherapy market in Asia.
LianBio (Nasdaq: LIAN) reported significant progress in its clinical development and regulatory submissions as of August 11, 2022. The company completed enrollment in the Phase 3 EXPLORER-CN trial of mavacamten in China, with topline data expected in mid-2023. LianBio submitted New Drug Applications for both mavacamten and infigratinib in Singapore and Hong Kong, respectively. Despite COVID-19 disruptions, cash reserves stood at $349.4 million, providing a runway into mid-2024. The firm anticipates launching three additional registration-enabling programs in China by year-end 2022.
LianBio (Nasdaq: LIAN) has completed enrollment in the Phase 3 EXPLORER-CN clinical trial for mavacamten, targeting symptomatic obstructive hypertrophic cardiomyopathy in Chinese patients. Despite COVID-related challenges, patient enrollment was rapid, reflecting strong demand for new therapies. Topline data is expected in mid-2023, which, if positive, will aid in a New Drug Application submission in China. Mavacamten has already received Breakthrough Therapy Designation in China and was FDA-approved in the U.S. for similar indications, highlighting its potential market impact.
LianBio (Nasdaq: LIAN) announced participation in upcoming investor conferences, including the Jefferies Healthcare Conference on June 10, 2022, and the Goldman Sachs Healthcare Conference on June 15, 2022. Both events will feature live audio webcasts accessible via the company's website. LianBio focuses on delivering innovative medicines to patients in China and other major Asian markets, advancing a diversified portfolio of product candidates across various therapeutic areas such as cardiovascular, oncology, and more.
